AbbVie acquires Celsius Therapeutics to enhance inflammatory disease treatment options
In a significant move within the biotechnology industry, AbbVie Inc. (NYSE: ABBV), a global biopharmaceutical company, has completed the acquisition of Celsius Therapeutics, Inc., a ... Read More
AbbVie’s SKYRIZI wins FDA approval for ulcerative colitis treatment
The U.S. Food and Drug Administration (FDA) has approved SKYRIZI (risankizumab-rzaa), an interleukin-23 (IL-23) inhibitor developed by AbbVie, for the treatment of adults with moderately ... Read More
AbbVie, FutureGen joins forces to pioneer next-gen IBD treatment FG-M701
In a significant development in the pharmaceutical industry, AbbVie Inc. (NYSE: ABBV) and FutureGen Biopharmaceutical (Beijing) Co., Ltd. have entered into a licensing agreement to ... Read More
AbbVie reports positive long-term results for atogepant in migraine prevention
AbbVie Inc. (NYSE: ABBV) has announced encouraging findings from an interim analysis of a 156-week extension study, assessing the long-term safety and effectiveness of atogepant, ... Read More
FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval ... Read More
Zydus Lifesciences, Daewoong Pharmaceutical forge US market alliance for Leuprolide Acetate
Zydus Worldwide DMCC, a wholly-owned subsidiary of Zydus Lifesciences Ltd., and South Korea's Daewoong Pharmaceutical Co., Ltd. have entered into a significant exclusive licensing agreement. ... Read More
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More
AbbVie to acquire ImmunoGen for $10.1bn to expand oncology portfolio
AbbVie Inc. and ImmunoGen Inc. have entered into a definitive agreement, marking a significant move in the pharmaceutical industry. AbbVie will acquire ImmunoGen, including its ... Read More
ABBV-RGX-314 : REGENXBIO reports positive Phase 2 data on diabetic retinopathy gene therapy candidate
REGENXBIO Inc. has disclosed new findings from its Phase II ALTITUDE trial, focusing on ABBV-RGX-314 as a gene therapy for diabetic retinopathy (DR) treatment. This ... Read More
AbbVie, Calibr to drive preclinical and clinical advancements in expanded partnership
AbbVie and Scripps Research institute’s division Calibr have announced a broadened strategic collaboration targeted at developing preclinical and early-stage clinical assets across a host of ... Read More